Astria Therapeutics, Inc.
Extract: Charter Amendment (Plain English Desc) (Inactive) from a 8-K on 09/08/2021   Download
SEC Document
SEC Filing

Effective as of September 8, 2021, Catabasis Pharmaceuticals, Inc. (the “Company”) amended its certificate of incorporation (as amended, the “Certificate of Incorporation”) to effect a change of the Company’s name from “Catabasis Pharmaceuticals, Inc.” to “Astria Therapeutics, Inc.” (the “Name Change”).

 

The Board of Directors of the Company (the “Board”) approved the Name Change pursuant to Section 242 of the General Corporation Law of the State of Delaware. The Name Change does not affect the rights of the Company’s stockholders and there were no other changes to the Certificate of Incorporation.